WHO Stops Clinical Trials Involving Hydroxychloroquine And HIV Drugs
Hydroxychloroquine And Lopinavir/Ritonavir Produced No Significant Results
Executive Summary
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”
You may also be interested in...
Novartis, Glenmark, Centrient Act To Tackle COVID-19 Crisis
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
Mylan Has Green Light On Remdesivir
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt
Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.